CRISPR tech may make gene editing unnecessary
Marsha Greene & Zubin Master, 2018, Senior Policy Analyst, Peraton & Biomedical Ethics Research Program, Mayo Clinic, https://www.ndu.edu/Portals/59/Documents/Incoming/AY21%20Briefings/NDU%206070/CRISPR_Military.pdf?ver=2020-08-11-170728-347, " Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement" Journal of Bioethical Inquiry (ermo/sms, Acc:6-8-2022)
More practically, the availability of CRISPR gene editing is likely to impact both policy and practice in warfighter health and performance research. CRISPR itself could be used to weaponize biological agents and the military will need to consider how the warfighter could be optimized for performance during a hypothetical attack (Hoehn et al. 2017). Historically, service members are often subject to mandatory vaccination programs to protect against biological agents while deployed. However, it may prove difficult to develop effective vaccines for some of these new and emerging biological threats. Initial work aimed at identifying candidate genes that confers sensitivity to anthrax could lay the ground work for these types of studies (Martchenko et al. 2012). Reduced expression of one such gene, capillary morphogenesis gene 2 (CMG 2), correlates strongly with lower susceptibility to anthrax. Interestingly, individuals who are closely related express CMG2 at similar levels which could indicate that sensitivity to these types of bioagents may be heritable traits. If genes such as CMG2 can be validated, the CRISPR system could be exploited in a variety of ways, some of which may not involve gene editing at all. In 2012, a team of researchers engineered a Cas9 enzyme that was unable to cut DNA (Qi et al. 2013). Essentially, the CRISPR/Cas9 machinery could be directed to a specific locus in the genome and used as either a gene promoter or suppressor, a sort of on/off switch for certain genes. More importantly, the effects could be reversible. One study did report targeted silencing of CMG receptors protected against anthrax toxin (Arévalo et al. 2014). Potential advantages are a shorter time frame between warfighter inoculation and deployment to a hostile zone and the ability to naturally reverse effects over time. More research is needed to determine the precise timing required for such inoculations and how long the expected response would be sustained.